Xenetic Biosciences Inc Market Cap ($4.83 Million)
Market Cap & Net Worth: Xenetic Biosciences Inc (XBIO)
Xenetic Biosciences Inc market cap. Xenetic Biosciences Inc (NASDAQ:XBIO) has a market capitalization of $4.83 Million ($4.83 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28609 globally and #5885 in its home market, demonstrating a 19.77% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xenetic Biosciences Inc's stock price $2.06 by its total outstanding shares 2343181 (2.34 Million). Also see XBIO cash generation efficiency for how efficiently the company converts equity into cash flow.
Xenetic Biosciences Inc Market Cap History (2015–2026)
Xenetic Biosciences Inc market cap history from 2015 to 2026. Data shows change from $4.73 Billion to $4.83 Million (-45.39% CAGR). Check XBIO stock price for real-time trading data and today's change.
Index Memberships
Xenetic Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.00% | #821 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #2629 of 3165 |
Weight: Xenetic Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Xenetic Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xenetic Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore XBIO net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.71x
Xenetic Biosciences Inc's market cap is 1.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.21 Billion | $3.00 Million | -$54.21 Million | 403.03x | N/A |
| 2017 | $539.45 Million | $7.58 Million | -$3.60 Million | 71.12x | N/A |
| 2019 | $33.74 Million | $17.07K | -$12.78 Million | 1977.14x | N/A |
| 2020 | $47.80 Million | $436.94K | -$10.89 Million | 109.40x | N/A |
| 2021 | $30.23 Million | $1.16 Million | -$5.65 Million | 26.04x | N/A |
| 2022 | $6.68 Million | $1.71 Million | -$6.55 Million | 3.91x | N/A |
| 2023 | $8.08 Million | $2.54 Million | -$4.13 Million | 3.18x | N/A |
| 2024 | $9.35 Million | $2.50 Million | -$3.96 Million | 3.74x | N/A |
| 2025 | $5.08 Million | $2.98 Million | -$2.68 Million | 1.71x | N/A |
Competitor Companies of XBIO by Market Capitalization
Companies near Xenetic Biosciences Inc in the global market cap rankings as of November 4, 2026. Also see XBIO asset base for a full breakdown of the balance sheet.
Key companies related to Xenetic Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Xenetic Biosciences Inc (2015–2026)
Market capitalization of Xenetic Biosciences Inc from 2015 to today. Between 2015 and today, Xenetic Biosciences Inc's market cap moved from $4.73 Billion to $ 4.83 Million, with a yearly change of -45.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.83 Million | -5.07% |
| 2025 | $5.08 Million | -45.61% |
| 2024 | $9.35 Million | +15.65% |
| 2023 | $8.08 Million | +21.01% |
| 2022 | $6.68 Million | -77.90% |
| 2021 | $30.23 Million | -36.76% |
| 2020 | $47.80 Million | +41.67% |
| 2019 | $33.74 Million | -92.68% |
| 2018 | $461.14 Million | -14.52% |
| 2017 | $539.45 Million | -55.38% |
| 2016 | $1.21 Billion | -74.45% |
| 2015 | $4.73 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Xenetic Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.83 Million USD |
| MoneyControl | $4.83 Million USD |
| MarketWatch | $4.83 Million USD |
| marketcap.company | $4.83 Million USD |
| Reuters | $4.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatmen… Read more